+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neoantigen Targeted Therapies Market - Global Forecast 2026-2032- Product Image
Neoantigen Targeted Therapies Market - Global Forecast 2026-2032- Product Image
New

Neoantigen Targeted Therapies Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896728
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Neoantigen Targeted Therapies Market is rapidly redefining the oncology landscape, offering tailored immunotherapy solutions that align with the latest clinical and technological advancements. Senior decision-makers seeking to capitalize on evolving trends in precision medicine and personalized cancer care will find this sector rich in actionable intelligence.

Market Snapshot: Neoantigen Targeted Therapies Market

In recent years, the Neoantigen Targeted Therapies Market advanced from USD 5.30 billion in 2025 to USD 6.15 billion in 2026, and is projected to achieve USD 15.61 billion by 2032 at a CAGR of 16.66%. This momentum highlights the market’s expanding role in transforming cancer treatment options, underpinned by growth in precision oncology and ongoing developments in immunotherapy. Market evolution reflects the shift toward innovative solutions that enhance patient outcomes and introduce new paradigms to traditional cancer management strategies.

Scope & Segmentation

This report delivers comprehensive coverage of the neoantigen targeted therapies value chain, presenting strategic insights across segments critical for executive planning:

  • Therapy Modalities: Emphasizes CAR-T cells, TCR therapy, tumor-infiltrating lymphocytes, and personalized vaccines using dendritic cells, nucleic acids, or synthetic peptides to expand treatment versatility in immuno-oncology.
  • Treatment Approaches: Covers both monotherapy and combination regimens incorporating checkpoint inhibitors and targeted biologics, addressing diverse patient requirements.
  • Administration Routes: Details oral and parenteral delivery, including intramuscular, intravenous, and subcutaneous methods, highlighting their impact on efficacy and the end-user experience.
  • Age Demographics: Addresses tailored therapy protocols for adult, geriatric, and pediatric groups, emphasizing differentiated safety and dosing strategies.
  • Disease Indications: Explores relevance across multiple cancers, such as bone, colorectal, gynecological, renal, and non-small cell lung cancers, demonstrating broad clinical applicability.
  • End Users: Analyzes the adoption within academic, government, hospital, and specialty centers, considering infrastructure needs and reimbursement dynamics.
  • Geographical Coverage: Studies adoption and strategic trends across the Americas, EMEA, and Asia-Pacific, focusing on regional health infrastructure, regulatory variation, and market access factors.
  • Technological Innovations: Outlines cutting-edge developments in next-generation sequencing, artificial intelligence, bioinformatics, and novel vaccine delivery mechanisms shaping current sector advances.

Key Takeaways for Senior Decision-Makers

  • Neoantigen targeted therapies are shaping a patient-specific approach to oncology, integrating immune modulation for targeted cancer intervention.
  • The combination of genomic profiling and predictive manufacturing accelerates development and drives market competitiveness by enabling swift candidate identification.
  • Strong collaboration among academic, biotech, and pharmaceutical partners is essential for translating breakthroughs into scalable clinical therapeutics.
  • Evolving regulatory models encourage adaptive clinical trial design and timely approvals, fueling dynamic product pipelines in this therapeutic sector.
  • Effective market access demands tailored strategies, considering demographic, treatment, and regional factors to enhance clinical integration and adoption.
  • Global expansion hinges on advancements in local infrastructure, reimbursement mechanisms, and region-specific market access approaches, requiring adaptive deployment strategies.

Tariff Impact: Navigating Trade Disruptions and Supply Chain Risks

The introduction of U.S. tariffs in 2025 has created challenges for manufacturers reliant on specialized reagents and components within the neoantigen targeted therapies market. In response, companies are diversifying suppliers, establishing new production capacities, and innovating to reduce exposure to fluctuating input costs. While these measures entail increased capital commitment, they are proving effective in fortifying supply chain resilience and ensuring ongoing operational stability even as the global trade landscape shifts.

Methodology & Data Sources

This analysis is grounded in a hybrid research model, combining primary interviews with industry leaders and regulatory experts and broad secondary research from published findings, clinical trials, and patent literature. Comprehensive data triangulation and independent verification ensure the reliability and accuracy of the insights presented.

Why This Report Matters

  • Empowers senior executives to anticipate market shifts, innovation catalysts, and risk exposure for optimized strategic planning.
  • Supports informed investment and partnership activities by highlighting regulatory, technology, and commercialization trends set to impact market success.
  • Enables targeted strategy development by leveraging actionable insights tied to segmentation and technology-driven opportunities.

Conclusion

Neoantigen targeted therapies are at the forefront of innovation in precision oncology. Leaders equipped with timely market insights can effectively shape strategies to navigate risk and capture emerging opportunities in a dynamic healthcare environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neoantigen Targeted Therapies Market, by Therapy Modality
8.1. Adoptive Cell Therapy
8.1.1. CAR-T Cell Therapy
8.1.2. T Cell Receptor (TCR) Therapy
8.1.3. Tumor-infiltrating lymphocytes (TIL)
8.2. Personalized Neoantigen Vaccines
8.2.1. Dendritic Cell (DC) Vaccines
8.2.2. DNA/ RNA-based Vaccines
8.2.3. Peptide (SLP) Vaccines
9. Neoantigen Targeted Therapies Market, by Treatment Approach
9.1. Combination Therapy
9.2. Monotherapy
10. Neoantigen Targeted Therapies Market, by Route of Administration
10.1. Oral
10.2. Parenteral
10.2.1. Intramuscular
10.2.2. Intravenous
10.2.3. Subcutaneous
11. Neoantigen Targeted Therapies Market, by Age Group
11.1. Adult
11.2. Geriatric
11.3. Pediatric
12. Neoantigen Targeted Therapies Market, by Target Disease Indication
12.1. Bone Cancer
12.2. Colorectal Cancer
12.3. Gynecological Cancer
12.4. Non-Small Cell Lung Cancer
12.5. Renal Cell Carcinoma
13. Neoantigen Targeted Therapies Market, by End-User
13.1. Academic & Government Research Institutes
13.2. Hospitals & Clinics
13.3. Specialty Clinics
14. Neoantigen Targeted Therapies Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Neoantigen Targeted Therapies Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Neoantigen Targeted Therapies Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Neoantigen Targeted Therapies Market
18. China Neoantigen Targeted Therapies Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Achilles Therapeutics Limited
19.6. Agenus Inc.
19.7. AstraZeneca plc
19.8. BioNTech SE
19.9. Bristol-Myers Squibb Company
19.10. CureVac N.V.
19.11. Eli Lilly and Company
19.12. EpiVax, Inc.
19.13. F. Hoffmann-La Roche AG
19.14. Genentech, Inc.
19.15. Genocea Biosciences, Inc.
19.16. Gilead Sciences, Inc.
19.17. GlaxoSmithKline plc
19.18. Gritstone bio, Inc.
19.19. Immatics N.V.
19.20. Immunomic Therapeutics, Inc.
19.21. IOVANCE Biotherapeutics, Inc.
19.22. Medigene AG
19.23. Merck & Co., Inc.
19.24. Moderna, Inc.
19.25. Neon Therapeutics, Inc.
19.26. Nykode Therapeutics
19.27. Pfizer Inc.
19.28. Precision Biologics
19.29. Valo Therapeutics Ltd
List of Figures
FIGURE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 133. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 134. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 135. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 137. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 138. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 139. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 150. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 152. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 153. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 154. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 155. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 157. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 158. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 159. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 173. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 174. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 175. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 176. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 178. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 179. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 180. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 181. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 183. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 184. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 185. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 186. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 188. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 189. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 190. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 201. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 203. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 204. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 205. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 206. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 208. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 209. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 210. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 211. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 212. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 213. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 214. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 215. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 216. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 218. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 219. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 220. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 221. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 222. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 223. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 224. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 225. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 226. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 228. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 229. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 230. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 231. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 242. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 243. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
TABLE 244. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 245. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
TABLE 246. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
TABLE 247. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 248. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 249. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 250. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 251. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Neoantigen Targeted Therapies market report include:
  • Achilles Therapeutics Limited
  • Agenus Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CureVac N.V.
  • Eli Lilly and Company
  • EpiVax, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genocea Biosciences, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Immatics N.V.
  • Immunomic Therapeutics, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neon Therapeutics, Inc.
  • Nykode Therapeutics
  • Pfizer Inc.
  • Precision Biologics
  • Valo Therapeutics Ltd

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.15 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.61 Billion
Compound Annual Growth Rate16.6%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Neoantigen Targeted Therapies Market Report 2025 - Product Image

Neoantigen Targeted Therapies Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026 - Product Image

CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026

  • Report
  • 120 Pages
  • Global
From
Global CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight 2026 - Product Image

Global CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight 2026

  • Report
  • 140 Pages
  • Global
From
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2025 - Product Image

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.